What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday?

Viking Therapeutics, Inc. (NASDAQ:VKTX),  Eli Lilly And Co (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) stocks are trading higher on Monday.

Pfizer Inc. (NYSE:PFE) announced on Monday that it will discontinue the development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1) receptor agonist being investigated for chronic weight management.

A single asymptomatic participant in one of the dose-optimization studies experienced potential drug-induced liver injury, which resolved after discontinuation of danuglipron.

Also Read: Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst

Pfizer is one of several drugmakers working to develop an alternative to injectable weight loss drugs. Still, it’s far behind rivals like Eli Lilly and Novo Nordisk, who already lead the market with weekly injections.

Eli Lilly is developing orforglipron, which could be the first small-molecule weight-loss pill when it launches in 2026. This would give Eli Lilly a two-year lead

https://www.benzinga.com/general/biotech/25/04/44791986/whats-going-on-with-viking-therapeutics-structure-therapeutics-stock-on-monday